Advagene Biopharma Co (ROCO:6709) Marketable Securities: NT$79.50 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6709 Advagene Biopharma Co Ltd ROCO:6709
30 GF Score
Price NT$25.00
! 2 Warning Signs
View Full Analysis

What is Advagene Biopharma Co Marketable Securities?

Advagene Biopharma Co ROCO:6709 -3.47% 30 Marketable Securities is NT$79.50 Mil as of Dec. 2025. GuruFocus rates ROCO:6709 with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Advagene Biopharma Co's Marketable Securities for the quarter that ended in Dec. 2025 was NT$79.50 Mil.

Advagene Biopharma Co's annual Marketable Securities increased from Dec. 2023 (NT$60.00 Mil) to Dec. 2024 (NT$149.50 Mil) but then declined from Dec. 2024 (NT$149.50 Mil) to Dec. 2025 (NT$79.50 Mil).

Advagene Biopharma Co  (ROCO:6709) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Advagene Biopharma Co Marketable Securities Related Terms

Advagene Biopharma Co Marketable Securities Historical Data

* Premium members only.

The historical data trend for Advagene Biopharma Co's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advagene Biopharma Co Marketable Securities Chart

Advagene Biopharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 209.50 85.00 60.00 149.50 79.50

Advagene Biopharma Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.00 59.50 149.50 149.50 79.50
ROCO:6709
30GF Score
Advagene Biopharma Co Ltd ROCO:6709
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Advagene Biopharma Co Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of NT$79.50 Mil mean?
Advagene Biopharma Co (ROCO:6709) has a Marketable Securities of NT$79.50 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Advagene Biopharma Co and its competitors.
Is Advagene Biopharma Co's Marketable Securities too high?
Advagene Biopharma Co's current Marketable Securities is NT$79.50 Mil. Overall, Advagene Biopharma Co has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Advagene Biopharma Co's Marketable Securities compare to VRTX and REGN?
Advagene Biopharma Co's Marketable Securities of NT$79.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Advagene Biopharma Co and its competitors. Advagene Biopharma Co's current Marketable Securities is NT$79.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advagene Biopharma Co stock overvalued right now?
Advagene Biopharma Co (ROCO:6709) has a current Marketable Securities of NT$79.50 Mil. The current Marketable Securities is NT$79.50 Mil. Advagene Biopharma Co's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Advagene Biopharma Co (ROCO:6709), the current Marketable Securities is NT$79.50 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advagene Biopharma Co Business Description

Address Sector 1, Neihu Road, 6 Floor, No.308, Neihu District, Taipei, TWN, 114
Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based biotechnology company. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray seasonal flu vaccine, nasal spray COVID-19 vaccine, Immunotherapy for COVID-19, Respiratory Allergy Immunotherapy - Allergic Rhinitis and Asthma ,and other vaccines.
30GF Score

Get the complete analysis for ROCO:6709

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$25.00
Price